DXRX — Diaceutics Cashflow Statement
0.000.00%
- £137.09m
- £127.84m
- £32.16m
- 83
- 16
- 55
- 49
Annual cashflow statement for Diaceutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.682 | 0.462 | 0.564 | -2.44 | -1.91 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.067 | 0.292 | 0.461 | -0.174 | 0.56 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.059 | -1.98 | 1.06 | -0.85 | -2.63 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.253 | 0.57 | 5.1 | 1.31 | 0.651 |
| Capital Expenditures | -6.29 | -5.6 | -4.87 | -4.86 | -4.63 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | 0.111 | 0.646 | 0.601 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -6.29 | -5.6 | -4.76 | -4.21 | -4.03 |
| Financing Cash Flow Items | 0 | -0.056 | -0.059 | -0.011 | -0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19.6 | -0.27 | -0.191 | -0.239 | -0.064 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.5 | -5.58 | 0.166 | -3.17 | -3.92 |